Baseline characteristics | Patients, N | SVR, N | Uninsured, N | Insured, N | P a |
---|---|---|---|---|---|
(% of all patients) | (% of group) | (% of uninsured) | (% of insured) | ||
All patients | 512 | 459 (90) | 289 (56) | 223 (44) | NS |
Sex, Male | 288 (56) | 252 (88) | 158 (55) | 130 (58) | NS |
Race | Â | Â | Â | Â | ** |
 White | 185 (36) | 161 (87) | 114 (39) | 71 (32) |  |
 Black | 223 (44) | 200 (90) | 107 (37) | 116 (52) |  |
 Hispanic | 81 (16) | 76 (94) | 50 (17) | 31 (14) |  |
 Other | 23 (5) | 22 (96) | 18 (6) | 5 (2) |  |
Age, Median (interquartile range) | 58 (54–62) | NA | 57 (53–61) | 59 (54–64) | ** |
BMI, Median (interquartile range) | 28 (25–33) | NA | 28 (25–33) | 28 (25–34) | NS |
Treatment-experienced | 80 (16) | 75 (94) | 36 (12) | 44 (20) | * |
Cirrhosis | 262 (51) | 227 (87) | 133 (46) | 129 (58) | * |
 Decompensated | 56 (11) | 46 (82) | 27 (9) | 29 (13) | NS |
HCV genotype | Â | Â | Â | Â | NS |
 Genotype 1a | 309 (60) | 273 (88) | 168 (58) | 141 (63) |  |
 Genotype 1b | 99 (19) | 91 (92) | 54 (19) | 45 (20) |  |
 Genotype 2 | 45 (9) | 41 (91) | 25 (9) | 18 (8) |  |
 Genotype 3 | 30 (6) | 27 (90) | 23 (8) | 7 (3) |  |
 Other genotypes | 29 (6) | 29 (100) | 19 (7) | 10 (4) |  |
Treatment regimen | Â | Â | Â | Â | NS |
 SOF + RBV | 52 (10) | 46 (88) | 30 (10) | 22 (10) |  |
 SMV + SOF ± RBV | 48 (9) | 39 (81) | 21 (7) | 27 (12) |  |
 DCV + SOF ± RBV | 26 (5) | 23 (88) | 15 (5) | 11 (5) |  |
 LDV + SOF ± RBV | 355 (69) | 323 (91) | 214 (74) | 141 (63) |  |
 OBV + PTV/r + DSV ± RBV | 27 (5) | 24 (89) | 7 (2) | 20 (9) |  |
 EBR + GZR | 4 (1) | 4 (100) | 2 (1) | 2 (1) |  |
HIV co-infected | 54 (11) | 47 (87) | 21 (7) | 33 (15) | ** |
Chronic HBV | 15 (3) | 14 (93) | 7 (2) | 8 (4) | NS |
Liver or kidney transplant | 23 (4) | 20 (87) | 9 (3) | 14 (6) | NS |
History of alcohol abuse | 208 (41) | 183 (88) | 109 (38) | 99 (44) | NS |
History of drug abuse | 255 (50) | 226 (89) | 141 (49) | 114 (51) | NS |
History of mental health disorder | 194 (38) | 172 (89) | 113 (39) | 81 (36) | NS |